New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
10:27 EDTBCRX, NNVC, HEB, TKMRMapp drug used to treat Ebola patients, CNN reports
A drug made by privately held Mapp Biopharmaceutical was used to treat the two Americans who contracted Ebola, CNN reports, citing a source familiar with details of the treatment. The experimental treatment called ZMapp had never been tried before in a human but had showed promise with monkeys, CNN adds. Shares of Tekmira (TKMR), NanoViricides (NNVC), BioCryst (BCRX) and Hemispherx (HEB) are moving higher in early trading after two Americans were flown home with Ebola. Reference Link
News For TKMR;NNVC;BCRX;HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
07:00 EDTBCRXBioCryst awarded $35M contract by BARDA for development of BCX4430
BioCryst Pharmaceuticals announced that the Biomedical Advanced Research and Development Authority, or BARDA, within the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, or ASPR, has awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This ASPR/BARDA contract includes a base contract of $12.1M to support BCX4430 drug manufacturing, as well as $22.9M in additional development options that can be exercised by the Government, bringing the potential value of the contract to $35.0M. Filoviruses represent serious threats to national security and the U.S. Government has made this a top priority for medical countermeasure development.
March 30, 2015
10:00 EDTTKMROn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:15 EDTTKMRTekmira initiated with a Buy at Nomura
Target $32.
March 25, 2015
19:34 EDTTKMRTekmira 'encouraged' by new preclinical data on TKM-HTG
Subscribe for More Information
March 24, 2015
08:35 EDTHEBHemispherx receives positive opinion on application for Orphan designation
Hemispherx Biopharma announces that the European subsidiary, "Hemispherx Biopharma Europe N.V./S.A" gained a positive opinion from the COMP (Committee on Medical Products) regarding its Orphan Medicinal Product Application for Ampligen, an experimental therapeutic, to treat Ebola Virus Disease, or EVD. The dossier submitted to the EU contained an inventory of relevant pre-clinical research in EVD therapeutically-oriented models, as well as, clinical safety information derived from non-EVD clinical studies of Ampligen. Of potentially high relevance to the favorable COMP opinion were experiments, conducted in Italy, which showed that, in vitro, Ampligen successfully competed with Ebola viral dsRNA in a manner which may result in loss of virulence by EBOV.
March 20, 2015
06:17 EDTTKMRTekmira 7.5M share Secondary priced at $20.25
Subscribe for More Information
March 19, 2015
09:20 EDTTKMROn The Fly: Pre-market Movers
Subscribe for More Information
07:14 EDTHEBWall Street Analyst Forum to hold a conference
25th Annual Investor Conference is being held in New York on March 19.
March 18, 2015
18:32 EDTTKMROn The Fly: After Hours Movers
UP AFTER EARNINGS: Guess (GES), up 12.4% after reporting fourth quarter results and guidance... Shoe Carnival (SCVL), up 10%... NQ Mobile (NQ), up 9.1%... Tilly's (TLYS), up 1.3%... Cintas (CTAS), up 1.3% after reporting quarterly results and raising fiscal 2015 guidance. DOWN AFTER EARNINGS: Williams-Sonoma (WSM), down 4.1%... Jabil Circuit (JBL), down 1.8%... Juno Therapeutics (JUNO), down 3.3%. ALSO LOWER: Concert Pharmaceuticals (CNCE), down 4.4% after filing to sell common stock... Tekmira Pharmaceuticals (TKMR), down 3.7% after filing to sell 6M shares of common stock.
16:19 EDTTKMRTekmira files to sell 6M shares of common stock
Leerink Partners LLC and RBC Capital Markets LLC are acting as joint lead book-runners for the offering. Nomura is acting as a book-runner for the offering. Co-managers for the offering are: JMP Securities, Wedbush PacGrow Life Sciences and Lazard Frères & Co.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use